Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Ok'd to Start China Trials of CD47 Immunotherapy

publication date: Jul 16, 2019

I-Mab Biopharma of Shanghai announced China approval to begin Phase I trials of its fully human CD47 mAb, which was developed to treat malignant tumors. Earlier this year, I-Mab was granted a similar approval in the US and reported the first patient dosing in June. I-Mab believes TJC4 has the potential to become a global best-in-class CD47 product because it binds to a unique epitope on CD47. This leads to minimal red blood cell binding, which allowed the molecule to avoid hemagglutination and anemia in preclinical tests. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here